In-DOTA TOC) have sole affinity for somatostatin receptor subtype 2 (sst 2 ). This represents a drawback, given that sst [1] [2] [3] [4] [5] have been shown to be over-expressed in different tumours, alone or concomitantly [1] . Our goal, therefore, was to develop radiopeptides with broader receptor subtype profiles.
68
Ga-DOTANOC is a first compound for PET imaging with high affinity for sst 2 and sst 5 [2] . Its affinity profile (IC 50 nM) for human sst [1] [2] [3] [4] [5] is, respectively, >10,000, 1.9± 0.4, 40±5.8, 260±74 and 7.2±1.6. For comparison, the values for the standard compound, 111 In-DOTATOC, are >10,000, 4.6±0.2, 120±26, 230±82 and 130±17.
Here we present the 60 min p.i.
Ga-DOTANOC PET images and the 21 h p.i.
111
In-DOTATOC planar images of a 52-year-old patient with an advanced neuroendocrine tumour. The two examinations were performed within 4 weeks. During this time interval the patient received bisphosphonates.
Preparation and application of 68 Ga-DOTANOC PET and 68 Ga-DOTATOC PET are comparable [3] . In the reported case study, the 68 Ga-DOTANOC PET scan shows high radioligand uptake in the liver and bone metastases. Although many bone metastases appeared visually similar in the two scans, the right sixth rib and left occipital bone metastases (arrows) are much more visible on the 68 Ga-DOTANOC PET scan. This selective difference cannot be explained simply by the advantages of the PET technique. The possible predominance of sst 5 in these two bone metastases and the high sst 5 affinity of In-DOTATOC uptake. The enlarged liver and somatostatin receptor-positive organs such as the spleen (high uptake) and pituitary gland and thyroid (moderate uptake) are also visible. These normal organs, known to express more sst than just sst 2 
